Literature DB >> 18211316

TASER X26 discharges in swine produce potentially fatal ventricular arrhythmias.

Robert J Walter1, Andrew J Dennis, Daniel J Valentino, Bosko Margeta, Kimberly K Nagy, Faran Bokhari, Dorion E Wiley, Kimberly T Joseph, Roxanne R Roberts.   

Abstract

OBJECTIVES: Data from the authors and others suggest that TASER X26 stun devices can acutely alter cardiac function in swine. The authors hypothesized that TASER discharges degrade cardiac performance through a mechanism not involving concurrent acidosis.
METHODS: Using an Institutional Animal Care and Use Committee (IACUC)-approved protocol, Yorkshire pigs (25-71 kg) were anesthetized, paralyzed with succinylcholine (SCh; 2 mg/kg), and then exposed to two 40-second discharges from a TASER X26 with a transcardiac vector. Vital signs, blood chemistry, and electrolyte levels were obtained before exposure and periodically for 48 hours postdischarge. Electrocardiograms and echocardiography (echo) were performed before, during, and after the discharges. p-Values < 0.05 were considered significant.
RESULTS: Electrocardiograms were unreadable during the discharges due to electrical interference, but echo images showed unmistakably that cardiac rhythm was captured immediately at a rate of 301 +/- 18 beats/min (n = 8) in all animals tested. Capture continued for the duration of the discharge and in one animal degenerated into fatal ventricular fibrillation (VF). In the remaining animals, ventricular tachycardia (VT) occurred postdischarge for 1-17 seconds, whereupon sinus rhythm was regained spontaneously. Blood chemistry values and vital signs were minimally altered postdischarge and no significant acidosis was seen.
CONCLUSIONS: Extreme acid-base disturbances usually seen after lengthy TASER discharges were absent with SCh, but TASER X26 discharges immediately and invariably produced myocardial capture. This usually reverted spontaneously to sinus rhythm postdischarge, but fatal VF was seen in one animal. Thus, in the absence of systemic acidosis, lengthy transcardiac TASER X26 discharges (2 x 40 seconds) captured myocardial rhythm, potentially resulting in VT or VF in swine.

Entities:  

Mesh:

Year:  2008        PMID: 18211316     DOI: 10.1111/j.1553-2712.2007.00007.x

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  7 in total

Review 1.  Repeated or long-duration TASER electronic control device exposures: acidemia and lack of respiration.

Authors:  James R Jauchem
Journal:  Forensic Sci Med Pathol       Date:  2010-03       Impact factor: 2.007

Review 2.  Blood lactate concentration after exposure to conducted energy weapons (including TASER® devices): is it clinically relevant?

Authors:  James R Jauchem
Journal:  Forensic Sci Med Pathol       Date:  2013-04-19       Impact factor: 2.007

3.  Physiological effects of the TASER C2 conducted energy weapon.

Authors:  James R Jauchem; Ronald L Seaman; Curtis M Klages
Journal:  Forensic Sci Med Pathol       Date:  2009-07-14       Impact factor: 2.007

4.  The physiologic effects of multiple simultaneous electronic control device discharges.

Authors:  Donald M Dawes; Jeffrey D Ho; Robert F Reardon; James D Sweeney; James R Miner
Journal:  West J Emerg Med       Date:  2010-02

5.  Acute effects of an alternative electronic-control-device waveform in swine.

Authors:  James Jauchem; Charles W Beason; Michael C Cook
Journal:  Forensic Sci Med Pathol       Date:  2009-03-28       Impact factor: 2.007

6.  Electromuscular incapacitating devices discharge and risk of severe bradycardia.

Authors:  Stepan Havranek; Petr Neuzil; Ales Linhart
Journal:  Am J Forensic Med Pathol       Date:  2015-06       Impact factor: 0.921

7.  Respiratory and Cardiovascular Response during Electronic Control Device Exposure in Law Enforcement Trainees.

Authors:  Kirsten M Vanmeenen; Marc H Lavietes; Neil S Cherniack; Michael T Bergen; Ronald Teichman; Richard J Servatius
Journal:  Front Physiol       Date:  2013-04-18       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.